Exact Therapeutics AS Total Liabilities

Latest as of December 2024: Nkr37.65 Million NOK ≈ $3.96 Million USD

Exact Therapeutics AS total liabilities. Based on the latest financial reports, Exact Therapeutics AS (EXTX) has total liabilities worth Nkr37.65 Million NOK (≈ $3.96 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Exact Therapeutics AS defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Exact Therapeutics AS (2017–2024)

Total liabilities of Exact Therapeutics AS from 2017 to 2024. This chart illustrates how Exact Therapeutics AS's total liabilities have evolved over time, based on quarterly financial data. Check Exact Therapeutics AS liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Exact Therapeutics AS Competitors by Total Liabilities

The table below lists competitors of Exact Therapeutics AS ranked by their total liabilities.

Company	Country	Total Liabilities
Trajano Iberia Socimi SA MC:YTRA	Spain	€85.60 Million
Imunon Inc NASDAQ:IMNN	USA	$10.80 Million
Suvidhaa Infoserve Limited NSE:SUVIDHAA	India	Rs353.50 Million
Craneware Plc LSE:CRW	UK	GBX213.50 Million
mTouche Technology Bhd KLSE:0092	Malaysia	RM19.25 Million
Zelira Therapeutics Ltd AU:ZLD	Australia	AU$5.59 Million
Ranplan Group ST:RPLAN	Sweden	Skr14.91 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Exact Therapeutics AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Exact Therapeutics AS asset portfolio.

Liquidity & Leverage Metrics

Exact Therapeutics AS Total Liabilities Ratios Explained

Exact Therapeutics AS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.54	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	2.65	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.33	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.25	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Exact Therapeutics AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Exact Therapeutics AS (2017–2024)

The table below shows the annual total liabilities of Exact Therapeutics AS from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	Nkr37.65 Million ≈ $3.96 Million	+132.15%
2023-12-31	Nkr16.22 Million ≈ $1.71 Million	-6.79%
2022-12-31	Nkr17.40 Million ≈ $1.83 Million	+46.38%
2021-12-31	Nkr11.89 Million ≈ $1.25 Million	+12.36%
2020-12-31	Nkr10.58 Million ≈ $1.11 Million	+7.21%
2019-12-31	Nkr9.87 Million ≈ $1.04 Million	+59.89%
2018-12-31	Nkr6.17 Million ≈ $649.40K	-47.15%
2017-12-31	Nkr11.68 Million ≈ $1.23 Million	--

About Exact Therapeutics AS

OL:EXTX Norway Biotechnology

Market Cap

$4.66 Million

Nkr44.28 Million NOK

Market Cap Rank

#28684 Global

#257 in Norway

Share Price

Nkr0.70

Change (1 day)

+40.56%

52-Week Range

Nkr0.48 - Nkr2.70

All Time High

Nkr40.90